Industry-Sponsored Research Week
University-Industry Engagement Advisor

Cambridge inks research partnership with Omeros Corp.


By David Schwartz
Published: December 18th, 2018

The University of Cambridge (UK) has entered a research collaboration with Omeros Corporation, and the two partners are establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR), where their research will be conducted.

The OC3IR is currently focusing on OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an enzyme of the complement system’s lectin pathway, and on OMS906, the company’s lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.

OMS721 is currently in three separate Phase 3 trials addressing stem cell transplant-associated thrombotic microangiopathy, IgA nephropathy, and atypical hemolytic uremic syndrome, respectively. OMS906 is slated to enter the clinic in early 2020.

The new center will be led by Wilhelm Schwaeble, DSc, Director of Research, working in close collaboration with other Cambridge complement researchers. One of the its priorities will be to characterize further the role and response of the complement system in endothelial injury, which is implicated in a wide range of diseases including thrombotic microangiopathies, kidney diseases and central nervous system disorders.

The Center will also help establish collaborations links between Omeros and other leading academic research laboratories in the field of complement and inflammation research. Any intellectual property resulting from Omeros-sponsored research at the OC3IR will be owned by Omeros, and Omeros will have an exclusive option to acquire all rights to intellectual property that is jointly supported by other funding sources.

“The University of Cambridge has a longstanding history of groundbreaking complement research, and we are excited to join forces with Omeros to continue advancing the translation of complement science,” said Professor Patrick Maxwell, DPhil, Regius Professor of Physic at Cambridge. “MASP-2 and MASP-3 are unique targets and hold significant advantages over other complement enzymes targeted by investigational or marketed drugs. MASP-2 and MASP-3 are increasingly implicated in an expanding array of severe disorders, and we look forward to working with Omeros for the betterment of patients.”

“This partnership represents a tremendous opportunity to benefit from the renowned complement and inflammation expertise at Cambridge,” added Gregory A. Demopulos, MD, chairman and CEO of Omeros.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection.

Source: Business Wire

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment